Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer

Che-Kai Tsao; Matthew D Galsky; William K Oh

doi:10.1016/j.eururo.2013.12.061

Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer

Eur Urol. 2014 Aug;66(2):184-5. doi: 10.1016/j.eururo.2013.12.061. Epub 2014 Jan 7.

Authors

Che-Kai Tsao¹, Matthew D Galsky¹, William K Oh²

Affiliations

¹ Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: William.oh@mssm.edu.

PMID: 24433812
DOI: 10.1016/j.eururo.2013.12.061

Abstract

Successful phenotype-genotype correlation is critically dependent on precise definition and reporting of end points in clinical trials. An uniform nomenclature for "deep phenotyping" of metastatic sites in patients with castration-resistant prostate cancer should be mandated in future clinical drug development.

Publication types

Editorial

MeSH terms

Clinical Trials as Topic / standards*
Humans
Male
Neoplasm Metastasis
Phenotype
Prostatic Neoplasms, Castration-Resistant / pathology*
Terminology as Topic*